Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history

Clinics and Research in Hepatology and Gastroenterology(2022)

Cited 4|Views15
No score
Abstract
•DEB-TACE achieves better short-term efficacy compared to cTACE.•HCC patients received DEB-TACE reaches longer survival profile than cTACE.•DEB-TACE (vs. cTACE) independently correlates with prolonged PFS and OS.•DEB-TACE displays similar safety profile as cTACE in treating HCC patients.
More
Translated text
Key words
Hepatocellular carcinoma,Conventional transarterial chemoembolization,Drug-eluting bead transarterial chemoembolization,Efficacy,Safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined